KalVista Pharmaceuticals Acquired by Chiesi | Healthcare M&A Deal

Chiesi has acquired KalVista Pharmaceuticals, a substance abuse treatment business in the healthcare sector. KalVista Pharmaceuticals develops therapies for rare disease patients, strengthening Chiesi’s global rare disease portfolio and expanding its specialty pipeline. Chiesi acquisitions in healthcare M&A are focused on adding differentiated medicines, and this strategic acquisition supports broader access to treatments for underserved populations. The platform acquisition is announced and sized as undisclosed, reflecting a strategic acquisition by a strategic buyer to accelerate long-term growth in rare disease and specialty care.